The most common statistical mistake made by oncologists: "Does not improve survival" is not the same as saying "it has not (yet) shown to improve survival." If the study is not designed and has the power to ask the first question, then no statements can be made about

We are steadily moving towards our goal... We would like to see you, meet and run together to fund further research... Together we can go a long distance and cure myeloma. Thanks Todd Kennedy Orange County MM group International Myeloma Foundation Yelak Biru . let's do this fundraise.myeloma.org/event/internat…

Beyond Clinical Trials: The Untapped Goldmine of Patient Experience A myeloma patient once told me, “The hardest part of my treatment isn’t the side effects—it’s the uncertainty between doctor visits.” This statement has stuck with me because it highlights something clinical

Carfilzomib (K) prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis. K 56/week as safe and effective as higher doses #mmsm Sharlene Dong Gurbakhash Kaur Rahul Banerjee, MD, FACP Vincent Rajkumar nature.com/articles/s4140…

Amrita Krishnan, M.D., our executive medical director of hematology, has hope after witnessing remarkable progress in myeloma treatment—helping patients achieve dreams, from weddings to graduations.💙 What gives you hope? We'd love to hear! 💬 Learn more:bit.ly/4ktrlIw

“We're going to stop calling myeloma an incurable cancer. I think in 2035, we'll be doing that.” Join Todd Kennedy—myeloma patient, support group leader, and research advocate—and his wife and care partner, Diane, as they share their transformative journey.youtube.com/watch?v=4jdRly…

“You know, cancer doesn't call ahead and ask, is this good for your schedule?” says Diane Kennedy, Todd Kennedy’s care partner. Life can surprise you—that’s why Diane Kennedy is passionate about caring for #carepartners too. Watch the full video now on myeloma.org

What an inspiring testimonial from Todd Kennedy, a patient advocate for the Alliance for Clinical Trials in Oncology Myeloma Committee, and his wife and care partner, Diane! #MyelomaMilestone #MyelomaActionMonth

Colorado CBCI; Alabama UAB O'Neal Comprehensive Cancer Center; NY Columbia University Raj Chakraborty; Tennesse @ Vanderbilt Bhagirath Dholaria, MD ; Wisconsin Medical College of Wisconsin Binod Dhakal and Madison Natalie Callander; Washington Fred Hutch Cancer Center Rahul Banerjee, MD, FACP Danai Dima ; Oregon OHSU Knight Cancer Institute R. Silberman and E. Medvedova.

Patient Reported Outcomes Measures… PRO CTCAE developed 15 years ago at NCI! Tolerability measures directly from patients are important. #AACR25 #AACRSSP

#ASCO25 | A wonderful opportunity to connect today w (L-R) patient advocate & advisor Todd Kennedy, Shaji Kumar, MD Shaji Kumar, and Diane Kennedy, patient & research advocate at the ENDURANCE (E1A11) poster| Abstract 7540 | ECOG-ACRIN ECOG-ACRIN Cancer Research Group National Cancer Institute Mayo Clinic #multiple myeloma

Key Myeloma therapy update for 2025 1) Newly diagnosed: Start treatment with quads, if possible. (Dara-VRd or Isa-VRd). 2) Auto Transplant: can be deferred for standard risk patients, especially if good response to induction. But collect and store stem cells for future use.

Major Regulatory Milestone in MM: In response to an application by I2TEAMM and International Myeloma Foundation, the European Medicines Agency has officially endorsed MRD as an early endpoint in clinical trials for Myeloma. This marks a transformative step forward in drug development !! Vincent Rajkumar

A historic day for myeloma!! After 5 decades of research. European Commission / EMA approves Daratumumab as the first ever approved treatment for high risk smoldering myeloma based on the results of the AQUILA trial. Thanos Dimopoulos Plasma Cell Pete globenewswire.com/news-release/2…

1/ Our call to action is out in Blood Advances! Title speaks for itself. Given concerningly high infection risk with bsAbs in myeloma #MMsm, IVIG/SCIG should be started regardless of any IgG threshold. Global authors & global audience, including insurance & healthcare funders.

Fully support this effort led by Rahul Banerjee, MD, FACP ! Infections = Number 1️⃣ driver of NRM with BsAb. But - We can do something about it and primary IVIG PPX has been shown to reduce mortality in this vulnerable patient collective. #startivig #dontwaitfortheinfection

Why New Patients With Multiple Myeloma ‘Can Expect Long, Healthy Lives’ curetoday.com/view/why-new-p… via CURE Today For most patients myeloma has become a chronic disease. @MyelomaTeacher - Cindy Chmielewski Yelak Biru Vincent Rajkumar Robin Tuohy

Myeloma is a curable disease now! #mmsm. ❤️🩸❤️🩸

Dr. Amrita Krishnan is an amazing mentor, colleague and a leader of the City of Hope Myeloma City of Hope | Orange County program and a national leader. Very pleased she is the SWOG chair and looking forward to the collaboration.

Just out in the New England Journal of Medicine! Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance NEJM nejm.org/doi/full/10.10… 5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and